Top news of the week: 21.01.2021.
Companies And Industries
Biden and biotech: Science first
The November election now seems such a long time ago: It has, in fact, been less than three months, but that time has been filled with political and scientific catastrophes that will shape ...
GSK, German Merck's $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer
A drug that Pfizer passed over but saw a revitalized cancer R&D-focused GlaxoSmithKline jump on for $4.2 billion has come up as a dud in a key trial pitting it against U.S. Merck’s ...
Roller coaster ride for Verastem continues as 2 weeks into the job, its CMO quits
After selling off its marketed cancer drug and focusing back on its pipeline after the loss of its CEO in 2019, Verastem started 2021 looking for stability in a new chief medical officer.
2021 Biopharma Update on the Novel Coronavirus: January 19
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 19, 2021.
Small biotech launches human trials of a potential ‘backstop’ for Covid-19 vaccines
"We all talk about pandemic preparedness. So that's what this is about," said Andrew Allen, CEO of Gritstone Oncology.
Spotlight On: Key biopharma events to watch in Q1
FirstWord Pharma - Gain Access to the Information You Need Track the Companies, Products, and Regulatory Areas of Most Interest to You
Stakeholder survey: Drug and device companies laud TGA’s pandemic response but want process improvements
PERTH, Australia – The majority of medical device and biopharma industry respondents agreed that Australia’s Therapeutic Goods Administration (TGA) responded effectively to COVID-19, but ...
After Moderna’s medical miracle, some investors step back
It was briefly the most highly valued biotech stock in Massachusetts. But is the company’s market value too lofty?